Biological Evaluation SR (BE-SR)

生物学评价 SR (BE-SR)

基本信息

批准号：
10434758
负责人：
BENNETT David ELZEY
金额：
$ 18.44万
依托单位：
PURDUE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-05-08 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10434758
关键词：
Adopted Animal Cancer Model Animal Experiments Animal Model Animals Antineoplastic Agents Applications Grants Area Autopsy Basic Science Behavior Biological Biology Bladder Cancer Biology Cancer Center Cancer Center Support Grant Cancer Model Canis familiaris Cell Line Characteristics Chemistry Clinical Trials Collaborations Consultations Data Development Diagnosis Discipline Disease Drug Kinetics Engineering Environment Evaluation Extramural Activities Familiarity Family Flow Cytometry Shared Resource Foundations Funding Future Human Human Cell Line Immunocompromised Host In Vitro Literature Malignant - descriptor Malignant Neoplasms Measures Methods Mission Modeling Molecular Mus NCI Center for Cancer Research Neoplasm Metastasis New Agents Nutritional Science Outcome Pathway interactions Peer Review Pharmacologic Substance Play Preclinical Testing Procedures Process Protocols documentation Publications Purdue Cancer Center Quality Control Regulation Reproducibility Reproducibility of Results Research Research Personnel Research Support Resource Sharing Role Safety Science Services Standardization Structure Technology Testing The Jackson Laboratory Tissues Toxic effect Toxicity Tests Toxicology Training Transgenic Animals Transplantation Tumor Cell Invasion Universities Validation Veterinary Medicine Veterinary Schools War Xenograft procedure animal model development anticancer research cancer type combat cost cost effective design drug development efficacy study experimental study in vivo in vivo evaluation lung small cell carcinoma member model design mouse model new technology novel strategies novel therapeutics patient derived xenograft model prevent prostate cancer model statistics tool translational study treatment response tumor tumor growth tumorigenesis validation studies

项目摘要

Biological Evaluation Shared Resource (BE-SR) Project Summary The discovery of new drug moieties to combat cancer is of paramount importance in overcoming this destructive family of diseases. In order to facilitate entry of new drugs into clinical trials, biological targets must be identified and validated, preliminary pharmacokinetics must be assessed, and initial toxicity/safety characteristics must be determined. Furthermore, new compounds must demonstrate sufficient efficacy in eliminating established tumors in animal models. In cancer biology, mouse models continue to play significant roles in studying tumor invasion, metastasis, and malignant transformation, as well as in examining responses to therapy. Towards this end, the use of mice for this testing is a cost-effective approach in early-stage evaluations, especially in a basic science research environment. Key advancements have emerged in the development of animal models for cancer biology, including the advent of orthotopic models for metastasis, transgenic animals that have developmental pathways to tumorigenesis, and state-of-the-art immunocompromised strains. In addition, transplanted human xenografts continue to serve as primary tools for molecular discovery and evaluation. Despite their flaws and shortcomings, xenograft mouse models have played a significant role in cancer drug development over the past three decades, and mouse models will continue to be a foundation in the war against cancer. At the Purdue University Center for Cancer Research (PCCR), where a vast pipeline of potential new agents for diagnosing and treating cancer are emerging, researchers need a productive and established facility for in vivo testing in murine cancer models. The mission of the Biological Evaluation Shared Resource (BE-SR) is to provide expert guidance to PCCR investigators in preparing grant proposals selecting animal models, designing animal studies, and performing toxicity testing and proof-of- concept efficacy studies to advance investigator's projects using in vivo testing. In keeping with the BE-SR's desire to offer the latest technologies in platform testing, the BE-SR has transitioned to using The Jackson Laboratory's highly immunocompromised NRG mice for xenograft studies with cell lines, and to using patient- derived xenograft (PDX) testing in this strain. These new services are just an example of the BE-SR's commitment to adopting new technologies and approaches into the PCCR in order to better serve the evolving needs of its researchers.

生物评估共享资源（BE-SR）项目摘要在克服这一点方面发现新药部分来打击癌症至关重要破坏性疾病家族。为了促进新药进入临床试验，必须被识别和验证，必须评估初步药代动力学，并初始毒性/安全性必须确定特征。此外，新化合物必须在消除动物模型中既定的肿瘤。在癌症生物学中，鼠标模型继续发挥重要作用研究肿瘤侵袭，转移和恶性转化以及检查反应中的作用接受治疗。为此，在此测试中使用小鼠是一种成本效益的方法评估，特别是在基础科学研究环境中。主要进步已经出现开发癌症生物学动物模型，包括转移的原位模型的出现，具有肿瘤发生的发育途径的转基因动物和最先进的动物免疫功能低下的菌株。此外，移植的人异种移植物继续作为主要工具分子发现和评估。尽管存在缺陷和缺点，但异种移植鼠标的模型仍在在过去的三十年中，在癌症药物开发中发挥了重要作用，小鼠模型将继续成为反对癌症战争的基础。在普渡大学癌症研究中心（PCCR），那里出现了大量潜在诊断和治疗癌症的新药物的渠道，研究人员需要一个鼠类癌模型中体内测试的生产和既定设施。生物学的任务评估共享资源（BE-SR）是为PCCR调查人员提供专家指导选择动物模型，设计动物研究以及进行毒性测试和证明证明的建议概念效能研究以使用体内测试来推进研究者的项目。与BE-SR保持一致渴望在平台测试中提供最新技术，BE-SR已过渡到使用杰克逊实验室的高度免疫功能低下的NRG小鼠用于用细胞系进行异种移植研究，并使用患者 - 在该菌株中衍生的异种移植（PDX）测试。这些新服务只是BE-SR的一个例子致力于采用新技术和方法进入PCCR，以更好地服务于不断发展的其研究人员的需求。